Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • COPD
Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial
Posted inClinical Updates

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

Posted by By MedXY 08/02/2025
Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.
Read More
  • Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance
  • Seasonal Malaria Chemoprevention in Uganda: Efficacy of SPAQ and Dihydroartemisinin-Piperaquine in the Era of Drug Resistance
  • Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
  • Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?
  • Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet exercise FDA FDA approval GLP-1 health healthcare HIV Hypertension immunotherapy lifestyle longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Pediatrics Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top